Tragedy of the anticommons

Last updated
Scientists are often reluctant to share their data. To deposit or not to deposit, that is the question - journal.pbio.1001779.g001.png
Scientists are often reluctant to share their data.

The tragedy of the anticommons is a type of coordination breakdown, in which a commons does not emerge, even when general access to resources or infrastructure would be a social good. It is a mirror-image of the older concept of tragedy of the commons, in which numerous rights holders' combined use exceeds the capacity of a resource and depletes or destroys it. [2] The "tragedy of the anticommons" covers a range of coordination failures, including patent thickets and submarine patents. Overcoming these breakdowns can be difficult, but there are assorted means, including eminent domain, laches, patent pools, or other licensing organizations.[ citation needed ]

Contents

The term originally appeared in Michael Heller's 1998 article of the same name [2] and is the thesis of his 2008 book. [3] The model was formalized by James M. Buchanan and Yong Yoon. [4] In a 1998 Science article, Heller and Rebecca S. Eisenberg, while not disputing the role of patents in general in motivating invention and disclosure, argue that biomedical research was one of several key areas where competing patent rights could actually prevent useful and affordable products from reaching the marketplace. [5]

Examples

In early aviation, the Wright brothers held patents on certain aspects of aircraft, while Glenn Curtiss held patents on ailerons which was an advance on the Wrights' system, but antipathy between the patent holders prevented their use. The government was forced to step in and create a patent pool during World War I. [6]

In his 1998 Harvard Law Review article, [2] Michael Heller noted that there were a lot of open air kiosks but also a lot of empty stores in many Eastern European cities after the fall of Communism. Upon investigation, he concluded that it was difficult or even impossible for a startup retailer to negotiate successfully for the use of that space because many different agencies and private parties had rights over the use of store space. Even though all the persons with ownership rights were losing money with the empty stores, and stores were in great demand, competing interests got in the way.

Heller says that the rise of the "robber barons" in medieval Germany was the result of the tragedy of the anticommons. [3] Nobles commonly attempted to collect tolls on stretches of the Rhine passing by or through their fiefs, building towers alongside the river and stretching iron chains to prevent boats from carrying cargo up and down the river without paying a fee. [3] Repeated attempts by the Holy Roman Empire, including several over the centuries by the Emperor, to regulate toll collection on the Rhine failed. And it was not until the establishment of the "Rhine League" of the Emperor with certain nobles and clergy that the "Robber barons" control over the Rhine was crushed. River tolls on the Rhine, increasingly imposed by states rather than individual lords, remained a sticking point in relations and commerce in the Rhine basin until the establishment of the Central Commission for Navigation on the Rhine in 1815.

Heller and Rebecca S. Eisenberg are academic law professors who believe that biological patents create a "tragedy of the anticommons", "in which people underuse scarce resources because too many owners can block each other." [5] Others claim that patents have not created this "anticommons" effect on research, based on surveys of scientists. [7] [8]

The housing crisis in many western cities can also be characterized as a tragedy of the anticommons. Zoning and planning processes give neighborhood groups, environmental groups and other stakeholders significant power over whether new housing projects move forward and on what terms. This creates a situation where many stakeholders have the right to exclude others from use of a private resource. [9] In many cases zoning and planning processes make it impossible for private landholders to construct new housing, especially multi-family housing. [10] This results in high prices, reduced inventory and significant homelessness. [11]

The Institute of Medicine highlighted an example of the tragedy of the anticommons in the context of data sharing clinical trial data in the medical field. Some notable challenges included protecting patient privacy, balancing conflicting interests, lack of standardization in data, ensuring data quality and integrity, and legal and regulatory barriers, which all contributed to issues regarding coordination and collaboration down the line. [12] This exemplifies the tragedy of the anticommons because the lower potential efficiency of clinical operation, as well as the satisfaction of patients, is compromised due to an underutilization of clinical data.

The ongoing legal battles between Apple Inc. and Samsung can be viewed as an example of the tragedy of the anticommons, specifically in intellectual property rights. Both Apple and Samsung own numerous patents related to mobile devices, [13] and the 10-year long legal dispute has been centred around patent infringement. This situation is a prime example of the tragedy of the anticommons, in the sense where many owners of a resource have the ability to exclude others from using it, leading to the underutilization of that resource. Apple Inc. and Samsung's limitations on their ability to innovate is an overall detriment to them, as well as the common people.

Several patent disputes halted the production of the COVID-19 vaccine during its inception. Some notable cases include Pfizer vs. Moderna, [14] Bharat Biotech vs. Serum Institute of India, [15] and Moderna vs. Arbutus. [16] These three cases are potentially a case of the tragedy of the anticommons. While the COVID-19 vaccine response was relatively quick, this was primarily due to scientists, doctors, ethics approval boards, manufacturers and regulatory agencies moving quickly in the state of emergency. [17] A patent dispute, in the sense of the tragedy of the anticommons, may have slowed down the production process, and limited the technology available, to competing firms. Patent disputes related to the COVID-19 vaccine are complex and often involve multiple parties and legal jurisdictions. The issues involved can be highly technical and may take years to resolve.

See also

Related Research Articles

<span class="mw-page-title-main">Patent</span> Type of legal protection for an invention

A patent is a type of intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. In most countries, patent rights fall under private law and the patent holder must sue someone infringing the patent in order to enforce their rights.

<span class="mw-page-title-main">Tragedy of the commons</span> Self-interests causing depletion of a shared resource

The tragedy of the commons is a metaphoric label for a concept that is widely discussed in economics, ecology and other sciences. According to the concept, should a number of people enjoy unfettered access to a finite, valuable resource such as a pasture, they will tend to over-use it, and may end up destroying its value altogether. To exercise voluntary restraint is not a rational choice for individuals – if they did, the other users would merely supplant them – yet the predictable result is a tragedy for all.

As with all utility patents in the United States, a biological patent provides the patent holder with the right to exclude others from making, using, selling, or importing the claimed invention or discovery in biology for a limited period of time - for patents filed after 1998, 20 years from the filing date.

Legal scholars, economists, activists, policymakers, industries, and trade organizations have held differing views on patents and engaged in contentious debates on the subject. Critical perspectives emerged in the nineteenth century that were especially based on the principles of free trade. Contemporary criticisms have echoed those arguments, claiming that patents block innovation and waste resources that could otherwise be used productively, and also block access to an increasingly important "commons" of enabling technologies, apply a "one size fits all" model to industries with differing needs, that is especially unproductive for industries other than chemicals and pharmaceuticals and especially unproductive for the software industry. Enforcement by patent trolls of poor quality patents has led to criticism of the patent office as well as the system itself. Patents on pharmaceuticals have also been a particular focus of criticism, as the high prices they enable puts life-saving drugs out of reach of many people. Alternatives to patents have been proposed, such Joseph Stiglitz's suggestion of providing "prize money" as a substitute for the lost profits associated with abstaining from the monopoly given by a patent.

<span class="mw-page-title-main">TRIPS Agreement</span> International treaty on intellectual property protections

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations. TRIPS was negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) between 1989 and 1990 and is administered by the WTO.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">Moderna COVID-19 vaccine</span> RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in people aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered as two or three 0.5 mL doses given by intramuscular injection at an interval of at least 28 days apart.

<span class="mw-page-title-main">Katalin Karikó</span> Hungarian-American biochemist (born 1955)

Katalin "Kati" Karikó is a Hungarian-American biochemist who specializes in ribonucleic acid (RNA)-mediated mechanisms, particularly in vitro-transcribed messenger RNA (mRNA) for protein replacement therapy. Karikó laid the scientific groundwork for mRNA vaccines, overcoming major obstacles and skepticism in the scientific community. Karikó received the Nobel Prize in Physiology or Medicine in 2023 for her work, along with American immunologist Drew Weissman.

<span class="mw-page-title-main">Drew Weissman</span> American physician and immunologist (born 1959)

Drew Weissman is an American physician and immunologist known for his contributions to RNA biology. Weissman is the inaugural Roberts Family Professor in Vaccine Research, director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).

<span class="mw-page-title-main">Deployment of COVID-19 vaccines</span> Distribution and administration of COVID-19 vaccinations

As of 13 November 2023, 13.53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">EpiVacCorona</span> EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology. The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature and in the media. The vaccine consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.

<span class="mw-page-title-main">UB-612</span> Vaccine candidate against COVID-19

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">NDV-HXP-S</span> Vaccine candidate against COVID-19

NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.

mRNA-1283 Vaccine candidate against COVID-19

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.

The TRIPS Agreement waiver is a joint intervention communication by South Africa and India to the TRIPS council of the World Trade Organization (WTO) on 2 October 2020.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">Initiative for Medicines, Access, and Knowledge</span> Nonprofit organization

The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global 501(c)(3) organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public.

References

  1. ↑ Roche, Dominique G.; Lanfear, Robert; Binning, Sandra A.; Haff, Tonya M.; Schwanz, Lisa E.; Cain, Kristal E.; Kokko, Hanna; Jennions, Michael D.; Kruuk, Loeske E. B. (2014). "Troubleshooting public data archiving: suggestions to increase participation". PLOS Biology . 12 (1): e1001779. doi: 10.1371/journal.pbio.1001779 . PMC   3904821 . PMID   24492920.
  2. 1 2 3 Heller, Michael A (January 1998). "The tragedy of the anticommons: property in the transition from Marx to markets" (PDF). Harvard Law Review. 111 (3): 621–688. doi:10.2307/1342203. ISSN   0017-811X. JSTOR   1342203. S2CID   154607436 . Retrieved 2018-03-16.
  3. 1 2 3 Heller, Michael (2008). The Gridlock Economy: How Too Much Ownership Wrecks Markets, Stops Innovation, and Costs Lives. Basic Books. ISBN   978-0-465-02916-7.
  4. ↑ Buchanan, James; Yoon, Yong (April 2000). "Symmetric Tragedies: Commons and Anticommons". Journal of Law and Economics. 43 (1): 1–13. CiteSeerX   10.1.1.320.7531 . doi:10.1086/467445. S2CID   2463182.
  5. 1 2 Heller, M. A.; Eisenberg, R. (May 1998). "Can Patents Deter Innovation? The Anticommons in Biomedical Research". Science . 280 (5364): 698–701. doi: 10.1126/science.280.5364.698 . PMID   9563938.
  6. ↑ "The Permission Problem". The New Yorker .
  7. ↑ Cook, Robert. "Gene Patents". The Hastings Center. Retrieved 2018-06-24.
  8. ↑ "Do Gene Patents Hurt Research?".
  9. ↑ Gebhardt, Matthew. "Planning, Property Rights and the Tragedy of the Anticommons: Temporary Uses in Portland and Detroit". Wiley-Blackwell. Retrieved 2023-09-10.
  10. ↑ "Zoning as a Barrier to Multifamily Housing Development" (PDF). American Planning Association. Retrieved 2023-09-10.
  11. ↑ Arnold, Chris. "'We Need To Build More Homes': Prices Soar Amid Housing Shortage". National Public Radio. Retrieved 2023-09-10.
  12. ↑ Institute of Medicine (2015). Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. National Academies Press. doi:10.17226/18998. ISBN   978-0-309-31629-3. PMID   25590113 . Retrieved 26 April 2023.
  13. ↑ Koetsier, John. "Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms". Forbes. Retrieved 26 April 2023.
  14. ↑ Brittain, Blake (6 December 2022). "Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents". Reuters. Retrieved 26 April 2023.
  15. ↑ Leo, Leroy (5 January 2021). "Serum Institute and Bharat Biotech call a truce, issue joint statement". mint. Retrieved 26 April 2023.
  16. ↑ "Arbutus Biopharma Corp. v. Moderna, Inc., Civil Action 22-252 | Casetext Search + Citator". casetext.com. Retrieved 26 April 2023.
  17. ↑ British Society for Immunology. "How have COVID-19 vaccines been developed so fast? | British Society for Immunology". www.immunology.org. Retrieved 26 April 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.